Migden, M. R.; Berkin, C.; Chang, A. L.; al., E. Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients With Locally Advanced Cutaneous Squamous Cell Carcinoma. J of Skin 2018, 2, S77.